Search…

China Biopharmaceuticals (01177): TQB6411 "EGFR/C-MET ADC" to announce Phase I clinical data at ASCO in 2026.

01/06/2026

The Zhixun Finance APP reports that China Biopharmaceutical (01177) has announced that its subsidiary ZhiDa Tianqing Pharmaceutical Group Co., Ltd. (ZhiDa Tianqing) has independently developed the national Class 1 innovative drug TQB6411 "EGFR/c-Met ADC". The first-in-human Phase I clinical study data in late-stage solid tumor patients was announced at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Latest

3 m ago

Microsoft will hold the Build 2026 developer conference on June 2-3 at Fort Mason in San Francisco, with the theme focusing on practical applications of cutting-edge AI technology. It is expected to release a series of new artificial intelligence models, including a code-specific model to enhance the competitiveness of its code assistant, GitHub Copilot. This tool, which previously held a first-mover advantage in the AI code assistance field, is now facing increasing competition from Cursor and Claude Code in market share.

3 m ago

The scale of the 7-day reverse repurchase maturity in the open market this week has expanded to 908.9 billion yuan, close to three times that of last week. There will be 800 billion yuan of 3-month period phased reverse repurchase maturing on Friday.

4 m ago

The Japanese Nikkei average index futures fell 0.1% in early trading.

4 m ago

Central finger research institute: the price decline of second-hand houses in 100 cities in May narrowed, and transactions remained active in key cities.

5 m ago

IG analyst Tony Sycamore pointed out in a report that concerns about mines in the Strait of Hormuz are escalating. This could delay the reopening of the strait, meaning that even if the strait reopens, relief in the oil market will come more slowly. "Even if an agreement is reached, it will not lead to a surge in supply," Sycamore said.

See all latest